AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2025
Nov 25, 2025
31542_dirs_2025-11-24_f7a4dd41-4391-4733-ab5d-da44df007a52.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2025-11-20
Reporting Person: Curran Daniel J. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-20 | Options to purchase common stock | $22.77 | A | 18115 | Acquired | 2032-11-20 | Common Stock (18115) | Direct |
| 2025-11-20 | Restricted Stock Units | $ | A | 5468 | Acquired | Common Stock (5468) | Direct |
Footnotes
F1: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
F2: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F3: Shares of common stock will be delivered to the Reporting Person upon vesting.
More from CATALYST PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 11
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Regulatory Filings
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6
Director's Dealing
2025
Dec 30